Alsachim and CIL join forces in the fight against COVID-19

Through a commercial partnership with Cambridge Isotope Labs (CIL), Alsachim is offering American researchers an assortment of unlabeled and stable isotope-labeled antiviral drug standards and their metabolites to assist in COVID-19 research and therapy development.

“We are thrilled to join forces with CIL in order to answer US customers’ needs and deliver crucial compounds for COVID-19 therapeutic monitoring” says, Dr. Jean-Francois Hoeffler, President of AlsaChim.

CIL’s Vice President of Sales and Marketing, Maureen Duffy added, “We are excited to partner with Alsachim to offer their high-quality drug standards to provide a much needed service to those U.S. pharmaceutical and biotech companies that are actively pursuing therapies to treat COVID-19”.

Through this affiliation, CIL and Alsachim will enhance worldwide coverage to provide researchers critical reagents to perform cutting-edge science in an effort to defeat the coronavirus pandemic.